Sikarin Upala from Bassett Medical Center: Using Caffeine to Slow Progression of Hepatitis C and Hepatic Fibrosis

Video

A recent study looked to shed light on the long-researched belief that caffeine decreases the risk of advanced hepatic fibrosis in people with hepatitis C.

A recent study looked to shed light on the long-researched belief that caffeine decreases the risk of advanced hepatic fibrosis in people with hepatitis C.

Sikarin Upala, MD, Bassett Medical Center, spoke about using caffeine to slow the progression of Hepatitis C and Hepatic Fibrosis during DDW 2016 in San Diego.

The research aimed to determine if there was any correlation between caffeine intake and hepatitis c infection or liver fibrosis. In the studies, caffeine beverages were consumed, whether one cup or several cups a day.

“We found those in the group who consumed caffeine reduced the risk of chronic Hepatitis C by 61 percent, compared to the group that did not have caffeine consumption,” Upala said.

The risk was specific to those who had hepatitis c and could then have advanced to liver cirrhosis as a result of that risk, he said. “Caffeine also helped improve the liver function of the caffeine group,” he added.

Upala said the research is significant because caffeine is so widely available in food and drink products. He recommended more studies, including randomized control trials, as his research was general data.

Also on MD Magazine >>> More news from Digestive Disease Week 2016

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.